Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CSL Behring
Biotech
Intellia showcases durability of one-and-done HAE option
The future of hereditary angiodema treatment seems to be coming down to how many shots it takes to reduce attacks.
Annalee Armstrong
Jun 2, 2024 8:00am
Ionis reveals oasis for HAE patients as RNA med reduces attacks
May 31, 2024 10:40am
CSL's largest ph. 3 trial ends in failure for heart attack drug
Feb 12, 2024 5:21am
Roche's executive dominoes continue to tip—Chutes & Ladders
Dec 16, 2022 9:30am
CSL Behring unveils its largest R&D site, slated to open in 2022
Sep 14, 2022 10:45am
FDA accepts CSL Behring’s gene therapy for speedy review
May 24, 2022 10:59am